特发性肺纤维化治疗药物研究进展  

Development of therapeutic drugs for idiopathic pulmonary fibrosis

作　　者：姜秋燕 梁庆 高劭妍 李霄鹤 黄慧[3] 周红刚[1,2] JIANG Qiu-yan;LIANG Qing;GAO Shao-yan;LI Xiao-he;HUANG Hui;ZHOU Hong-gang(College of Pharmacy,JSankai University,State Key Lab of Medicinal Chemical Biology,Tianjin 300350,China;Tianjin International Joint Academy of Biomedicine,Tianjin 300070,China;Department of Respiratory and Critical Care Medicine,Peking Union Medical College Hospital,Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing 100730,China)

机构地区：[1]南开大学药学院,南开大学药物化学生物学国家重点实验室,天津300350 [2]天津国际生物医药联合研究院,天津300070 [3]中国医学科学院北京协和医学院北京协和医院呼吸与危重症医学科,北京100730

出　　处：《中国新药杂志》2021年第14期1274-1281,共8页Chinese Journal of New Drugs

摘　　要：特发性肺纤维化(idiopathic pulmonary fibrosis, IPF)是最常见、致命性、病因不明的间质性肺病,目前认为是反复的肺泡上皮细胞损伤引起的异常修复导致肺功能丧失的过程。目前全球范围内仅有吡非尼酮和尼达尼布被批准用于治疗IPF,抗肺纤维化药物治疗手段仍亟待开发。由于已上市药物的药动学以及安全性资料较为详尽,研发周期大大缩短,"老药新用"策略的出现给研究者们带来了希望。本文就已上市的不同种类药物在抗肺纤维化中的基础研究进行汇总,为抗肺纤维化药物开发提供参考。Idiopathic pulmonary fibrosis(IPF) is the most common, fatal interstitial lung disease with unknown etiology. The current hypothesis is that sustained injury imposed on alveolar epithelial cells leads to aberrant wound healing and finally pulmonary function failure. The unknown pathogenesis heightens the difficulty for anti-fibrosis drug development. Only two drugs, pirfenidone and nintedanib, are approved for IPF treatment, and medical therapies against IPF are still in urgent need. Now researchers are focusing on new indications development for approved drugs since they have relatively detailed pharmacokinetics and safety data. Thus, effective drugs will rapidly go to clinical trials, and the development cycle will be greatly shortened. Here we summarize the basic science studies for different types of approved drugs against IPF and hope to provide reference for development of anti-fibrosis drugs.

关 键 词：特发性肺纤维化 上市药物 新适应证开发 基础研究 

分 类 号：R994.1[医药卫生—毒理学]